Skip to main content

Danaher Value Stock - Dividend - Research Selection

Danaher

ISIN: US2358511028 , WKN: 866197

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company\'s Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. Its Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and flow cytometry products. The company offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians\' offices, reference laboratories, and other critical care settings. Its Dental segment provides consumables, equipment, and services to diagnose, treat, and prevent disease and ailments of the teeth, gums, and supporting bone. This segment offers implant systems, dental prosthetics, and associated treatment planning software; orthodontic bracket systems and lab products; endodontic systems and related consumables; restorative materials and instruments; infection prevention products; digital imaging systems and software; air and electric powered handpieces, and consumables; and treatment units. Its Environmental & Applied Solutions segment offers instrumentation, services, and disinfection systems to analyze, treat, and manage water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for packaging, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


BLCO or DHR: Which Is the Better Value Stock Right Now?

2026-02-09
BLCO vs. DHR: Which Stock Is the Better Value Option?

Calculating The Fair Value Of Danaher Corporation (NYSE:DHR)

2026-02-09
Key Insights Danaher's estimated fair value is US$237 based on 2 Stage Free Cash Flow to Equity Current share price of...

A Look At Danaher (DHR) Valuation After Earnings And 2026 Targets Reaffirm Growth Story

2026-02-05
Danaher (DHR) is back in focus after its latest earnings, where revenue met Wall Street expectations and bioprocessing plus diagnostics helped support the outlook alongside new 2026 growth and profit targets. See our latest analysis for Danaher. Danaher shares have been choppy around the latest earnings release, with a recent 1 day share price return of 1.35% and a 30 day share price return showing a 6.73% decline, while the 1 year total shareholder return of 4.14% points to relatively modest...

Cleveland Diagnostics Names Jack Kenny as Chairman of the Board

2026-02-05
CLEVELAND, February 05, 2026--Cleveland Diagnostics Names Jack Kenny as Chairman of the Board

Exclusive: Lawhive, a startup using AI to reimagine the general practice law firm, raises $60 million in new venture capital funding

2026-02-05
The startup offers routine legal services using human lawyers assisted by AI software.

Danaher Corporation (DHR): A Bull Case Theory

2026-02-04
We came across a bullish thesis on Danaher Corporation on Heavy Moat Investments’s Substack. In this article, we will summarize the bulls’ thesis on DHR. Danaher Corporation’s share was trading at $224.54 as of January 28th. DHR’s trailing and forward P/E were 48.51 and 27.62 respectively according to Yahoo Finance. Danaher Corporation designs, manufactures, and markets professional, medical, research, […]

The Top 5 Analyst Questions From Danaher’s Q4 Earnings Call

2026-02-04
Danaher’s fourth quarter results met Wall Street’s revenue expectations, with management attributing performance to ongoing strength in its bioprocessing segment and steady growth in diagnostics. CEO Rainer Blair noted that bioprocessing consumables demand, especially for monoclonal antibodies, remained robust, while diagnostic platforms benefited from an active respiratory season and expanding test menus. However, management acknowledged ongoing softness in academic and government research fund

Danaher: The Worst Should Be Over, But Valuation Is Still Tight (Rating Downgrade)

2026-02-04

Veralto (NYSE:VLTO) Misses Q4 CY2025 Sales Expectations

2026-02-03
Water analytics and treatment company Veralto (NYSE:VLTO) missed Wall Street’s revenue expectations in Q4 CY2025 as sales rose 3.8% year on year to $1.40 billion. Its non-GAAP profit of $1.04 per share was 6% above analysts’ consensus estimates.

Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter

2026-02-02
Feb 2 (Reuters) - Medical equipment maker Revvity handily beat fourth-quarter estimates and forecast 2026 revenue and profit above Wall Street expectations on Monday, betting on continued strength in